protein

TAU

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

6171Connections
30Hypotheses
24Analyses
50Outgoing
50Incoming
0Experiments
20Debates

Summary

Microtubule-associated protein tau (MAPT) stabilizes neuronal microtubules. Hyperphosphorylation causes detachment and aggregation into neurofibrillary tangles, a hallmark of Alzheimer disease and other tauopathies. Pathological tau spreads trans-synaptically and drives neuronal dysfunction.

View on Wiki →

No AI portrait yet

🔬 Protein Info
Gene SymbolJNJ
Full Name63733657: Anti-Tau Monoclonal Antibody for Early Alzheimer's Disease
AliasesTAU
Chromosome17q21.31
Protein FamilyMAPT family
Functionis an important component in the neurobiology of neurodegenerative diseases.
Primary Expressionneurons, where they bind to microtubules and promote their polymerization and stability
Subcellular LocalizationAxons, Neurons
Molecular Weight45-65 kDa (isoform dependent)
Amino Acids441 aa
PathwaysExtracellular Aggregation, Hyperphosphorylation, Neurofibrillary Tangle Formation, Protein Assembly, Synapse Pathology
GeneCardsJNJ
Human Protein AtlasJNJ
Neurofibrillary tangle formationPaired helical filaments of hyperphosphorylated tau accumulate in neurons
Microtubule dysfunctionLoss of tau's ability to stabilize microtubules disrupts axonal transport
Associated DiseasesAD, Aging, Als, Alzheimer, Alzheimer Disease
Known Drugs/Compounds12A12, Disease-modifying therapy, DONANEMAB, DONEPEZIL, Flavonoids, Hyperbaric Oxygen Therapy
InteractionsAB, ABCA1, ABCA7, ABI3, ACE, ACE2
KG Connections5894 knowledge graph edges
DatabasesGeneCardsUniProtNCBI GeneHPASTRING

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

nct04619420

clinical_trial · 1578 words

AMX0035 CENTAUR Trial

clinical · 1579 words

STAU2 Gene

gene · 711 words

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        TAU["TAU"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
        TAU["TAU"] -->|"associated with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
        TAU["TAU"] -->|"associated with"| TAUOPATHY["TAUOPATHY"]
        TAU["TAU"] -->|"associated with"| Alzheimer_2["Alzheimer"]
        AMYLOID["AMYLOID"] -->|"associated with"| TAU["TAU"]
        MICROGLIA["MICROGLIA"] -->|"associated with"| TAU["TAU"]
        NEUROINFLAMMATION["NEUROINFLAMMATION"] -->|"associated with"| TAU["TAU"]
        AUTOPHAGY["AUTOPHAGY"] -->|"associated with"| TAU["TAU"]
        APP["APP"] -->|"associated with"| TAU["TAU"]
        ALS["ALS"] -->|"associated with"| TAU["TAU"]
    end
    subgraph Signaling["Signaling"]
        TAU["TAU"] -->|"activates"| NEURODEGENERATION_1["NEURODEGENERATION"]
        TAU["TAU"] -->|"activates"| Alzheimer["Alzheimer"]
        TAU["TAU"] -->|"activates"| Als["Als"]
        TAU["TAU"] -->|"activates"| Autophagy["Autophagy"]
        TAU["TAU"] -->|"activates"| Oxidative_Stress["Oxidative Stress"]
    end
    style TAU fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style NEURODEGENERATION fill:#5d4400,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEURODEGENERATION_1 fill:#5d4400,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style TAUOPATHY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Oxidative_Stress fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer_2 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEUROINFLAMMATION fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AUTOPHAGY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (3096)

TargetRelationTypeStr
GLUTAMATEassociated_withprotein1.00
TAU PATHOLOGYassociated_withgene1.00
ALZHEIMERbiomarker_forgene1.00
DEMENTIAbiomarker_forgene1.00
ALZHEIMER'S DISEASEinhibitsgene1.00

Incoming (3075)

SourceRelationTypeStr
entities-buntanetapinteracts_withwiki0.00
entities-histone-deacetylaseinteracts_withwiki0.00
entities-ampkinteracts_withwiki0.00
entities-prx005interacts_withwiki0.00
entities-fdg-petinteracts_withwiki0.00

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 0.938 molecular neurobiology View
Closed-loop transcranial focused ultrasound targeting EC-II 0.922 Alzheimer's disease Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting EC-II SST interneur 0.900 Alzheimer's disease Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II SST interneurons to block t 0.896 Alzheimer's disease Circuit-level neural dynamics in neurode
GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl 0.869 neuroscience Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II PV interneurons to enhance 0.867 Alzheimer's disease Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting EC-II PV interneuro 0.863 Alzheimer's disease Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II PV interneurons to suppress 0.857 Alzheimer's disease Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II parvalbumin interneurons to 0.831 Alzheimer's disease Circuit-level neural dynamics in neurode
Beta-frequency entrainment therapy targeting PV interneuron- 0.827 Alzheimer's disease Circuit-level neural dynamics in neurode
Glymphatic-Mediated Tau Clearance Dysfunction 0.821 neuroscience Circuit-level neural dynamics in neurode
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular 0.812 neuroscience Circuit-level neural dynamics in neurode
LRP1-Dependent Tau Uptake Disruption 0.808 neurodegeneration Tau propagation mechanisms and therapeut
Closed-loop transcranial focused ultrasound targeting CA1 PV 0.797 Alzheimer's disease Circuit-level neural dynamics in neurode
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign 0.792 neuroscience Circuit-level neural dynamics in neurode
CYP46A1 Suppression for Tau-Mediated Neurodegeneration 0.792 neurodegeneration Lipid raft composition changes in synapt
Excitatory Neuron Synaptic Dysfunction and Mitochondrial Str 0.790 neurodegeneration Cell type vulnerability debate in Alzhei
Closed-loop tACS targeting entorhinal cortex layer II SST in 0.784 Alzheimer's disease Circuit-level neural dynamics in neurode
TREM2-mediated microglial tau clearance enhancement 0.780 neurodegeneration Tau propagation mechanisms and therapeut
Sleep-Dependent Glymphatic Clearance Expands the Therapeutic 0.780 neurodegeneration What is the therapeutic window between t
Lysosomal Cathepsin-Dependent Tau Clearance 0.767 neurodegeneration View
cGAS-STING Pathway Hyperactivation Mediates Tau Propagation 0.760 neurodegeneration Gap 006 analysis (archived stub)
Dual-Circuit Tau Vulnerability Cascade 0.754 neuroscience Circuit-level neural dynamics in neurode
Enhancing Microglial Phagocytosis of Extracellular Tau via T 0.750 neuroscience Trans-synaptic tau spreading and propaga
VPS35 retromer activation prevents endosomal tau templating 0.740 neurodegeneration Which tau propagation mechanism predomin
Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Ne 0.740 neuroscience Trans-synaptic tau spreading and propaga
Tau missorting transitions into an autonomous tau-seeding st 0.740 neurodegeneration Does tau dendritic missorting persist in
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece 0.737 neuroscience Circuit-level neural dynamics in neurode
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in 0.735 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro
Noradrenergic-Tau Propagation Blockade 0.711 neurodegeneration Sleep disruption as cause and consequenc

Mentioning Analyses (24)

Scientific analyses that reference this entity

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

neurodegeneration | 2026-04-16 | 0 hypotheses

Gene Co-expression Network Analysis of AD Progression Modules

neurodegeneration | 2026-04-16 | 0 hypotheses

Extracellular vesicle biomarkers for early AD detection

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.665

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

drug discovery | 2026-04-09 | 0 hypotheses

Epigenetic reprogramming in aging neurons

neurodegeneration | 2026-04-04 | 9 hypotheses Top: 0.914

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (20)

Multi-agent debates referencing this entity

Investigate prion-like spreading of tau pathology through connected brain region

closed · Rounds: 4 · Score: 0.73 · 2026-04-22

What co-expression modules are shared and unique across brain regions in AD, and

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Which clinical, genetic, and biomarker features are independent prognostic marke

closed · Rounds: 4 · Score: 0.60 · 2026-04-21

Is a 3-marker prognostic index clinically actionable for MCI patients, or does t

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Is TYROBP a genuine therapeutic target in AD, or is it a downstream marker of mi

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Investigate prion-like spreading of tau pathology through connected brain region

closed · Rounds: 4 · Score: 0.90 · 2026-04-12

Protein aggregation cross-seeding across neurodegenerative diseases?

closed · Rounds: 4 · Score: 0.70 · 2026-04-12

Which EV-derived biomarkers (phospho-tau, amyloid-beta, synaptic proteins, infla

closed · Rounds: 4 · Score: 0.75 · 2026-04-12

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12